Observational studyAnnals of hematology2021

Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome.

Dolores Subirá et al.PubMed ↗Publisher ↗

No numbers read from the abstract.